Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener
Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
| P | 11 | +0 | +3 | -2 | +0 |
| S | 42 | -0 | -2 | -1 | +0 |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2017-07-20 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale+OE | $131.09 | -6,485 | 18,165 | -26% | -$850,119 | |||||
2017-07-17 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale | $101.38 | -200 | 14,701 | -1% | -$20,276 | ||||||
| D | 2017-07-17 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale+OE | $100.81 | -3,830 | 14,901 | -20% | -$386,103 | |||||
2017-06-30 | HPPI | Hedgepath Pharmaceuticals, Inc. | Hedgepath, LLC | 10% | S - Sale | $0.00 | -2,500,000 | 79,627,069 | -3% | -$0 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $100.02 | -500 | 346,518 | 0% | -$50,008 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $99.30 | -5,720 | 336,678 | -2% | -$568,011 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $99.07 | -9,264 | 342,398 | -3% | -$917,818 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $98.92 | -9,516 | 351,662 | -3% | -$941,337 | ||||||
| D | 2017-07-05 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $126.18 | -3,000 | 12,148 | -20% | -$378,540 | |||||
| D | 2017-07-03 | INCY | Incyte Corp | Siegel Eric H. | EVP, GC | S - Sale+OE | $126.20 | -1,820 | 18,216 | -9% | -$229,684 | |||||
| D | 2017-07-03 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $35.21 | -1,987 | 63,666 | -3% | -$69,962 | |||||
| D | 2017-06-30 | INCY | Incyte Corp | Gryska David W | EVP, CFO | S - Sale+OE | $129.74 | -599 | 19,015 | -3% | -$77,714 | |||||
| DM | 2017-06-30 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.08 | -2,785 | 32,600 | -8% | -$75,430 | |||||
| DM | 2017-07-03 | INCR | Inc Research Holdings, Inc. | Gaenzle Christopher L | CAO, GC, Sec | S - Sale+OE | $58.32 | -6,873 | 46,494 | -13% | -$400,846 | |||||
| DM | 2017-06-30 | INCR | Inc Research Holdings, Inc. | Macdonald Alistair | CEO | S - Sale+OE | $58.38 | -10,555 | 73,380 | -13% | -$616,159 | |||||
| D | 2017-06-29 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.00 | -846 | 32,600 | -3% | -$22,842 | |||||
| DM | 2017-06-27 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.13 | -5,059 | 32,600 | -13% | -$137,241 | |||||
| DM | 2017-06-23 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.18 | -9,635 | 32,600 | -23% | -$261,918 | |||||
| D | 2017-06-22 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.25 | -209 | 32,600 | -1% | -$5,696 | |||||
| D | 2017-06-22 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale+OE | $100.00 | -43,154 | 371,518 | -10% | -$4,315,400 | |||||
| D | 2017-06-22 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale+OE | $100.00 | -10,948 | 63,566 | -15% | -$1,094,800 | |||||
| DM | 2017-06-20 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.38 | -2,159 | 32,600 | -6% | -$59,113 | |||||
| D | 2017-06-20 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale+OE | $125.00 | -9,883 | 14,648 | -40% | -$1,235,375 | |||||
| DM | 2017-06-16 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.53 | -11,168 | 32,600 | -26% | -$307,401 | |||||
| DM | 2017-06-14 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.98 | -4,640 | 32,600 | -12% | -$129,820 | |||||
2017-06-15 | SRNE | Sorrento Therapeutics, Inc. | Ji Henry | Pres, CEO | P - Purchase | $1.81 | +29,001 | 2,289,870 | +1% | +$52,562 | ||||||
2017-06-15 | SRNE | Sorrento Therapeutics, Inc. | Shah Jaisim | Dir | P - Purchase | $1.79 | +10,002 | 112,633 | +10% | +$17,904 | ||||||
| D | 2017-06-12 | INCY | Incyte Corp | Gryska David W | EVP, CFO | S - Sale+OE | $116.60 | -16,756 | 19,015 | -47% | -$1,953,750 | |||||
| D | 2017-06-08 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $95.00 | -945 | 13,258 | -7% | -$89,775 | |||||
| D | 2017-06-05 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $132.50 | -3,000 | 10,950 | -22% | -$397,500 | |||||
2017-05-31 | Q | Quintiles Ims Holdings, Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | Dir, 10% | S - Sale | $84.01 | -5,154,936 | 36,935,608 | -12% | -$433,066,173 | ||||||
| D | 2017-06-01 | INCY | Incyte Corp | Siegel Eric H. | EVP, GC | S - Sale+OE | $130.00 | -1,820 | 16,924 | -10% | -$236,600 | |||||
2017-05-31 | INCY | Incyte Corp | Bienaime Jean Jacques | Dir | P - Purchase | $131.80 | +500 | 4,677 | +12% | +$65,900 | ||||||
2017-05-31 | Q | Quintiles Ims Holdings, Inc. | Connaughton John | Dir | S - Sale | $84.01 | -1,087,786 | 8,726,148 | -11% | -$91,384,902 | ||||||
2017-05-30 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $18.46 | -5,000 | 135,686 | -4% | -$92,300 | ||||||
2017-05-31 | Q | Quintiles Ims Holdings, Inc. | Gillings Dennis B Ph D | Dir | S - Sale | $84.01 | -860,000 | 10,123,929 | -8% | -$72,248,600 | ||||||
2017-05-31 | Q | Quintiles Ims Holdings, Inc. | Cpp Investment Board Private Holdings, Inc. | 10% | S - Sale | $84.01 | -7,131,165 | 17,038,426 | -30% | -$599,089,172 | ||||||
2017-05-30 | Q | Quintiles Ims Holdings, Inc. | Danhakl John G | Dir | S - Sale | $84.01 | -761,143 | 5,453,659 | -12% | -$63,943,623 | ||||||
| D | 2017-05-26 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale+OE | $92.84 | -10,976 | 63,566 | -15% | -$1,019,022 | |||||
| D | 2017-05-17 | Q | Quintiles Ims Holdings, Inc. | Greenberg Jack M | Dir | S - Sale+OE | $82.50 | -6,092 | 27,930 | -18% | -$502,590 | |||||
2017-05-15 | INCY | Incyte Corp | Bienaime Jean Jacques | Dir | P - Purchase | $115.00 | +500 | 4,177 | +14% | +$57,500 | ||||||
| D | 2017-05-15 | EXEL | Exelixis, Inc. | Feldbaum Carl B | Dir | S - Sale+OE | $21.58 | -32,988 | 34,733 | -49% | -$711,831 | |||||
2017-05-12 | CASC | Cascadian Therapeutics, Inc. | Myers Scott Dunseth | Pres, CEO | P - Purchase | $4.00 | +2,800 | 44,216 | +7% | +$11,192 | ||||||
2017-05-12 | CRL | Charles River Laboratories International Inc | Kochevar Deborah Turner | Dir | S - Sale | $88.03 | -300 | 8,486 | -3% | -$26,408 | ||||||
| D | 2017-05-12 | CRL | Charles River Laboratories International Inc | Kochevar Deborah Turner | Dir | S - Sale+OE | $87.93 | -7,070 | 8,786 | -45% | -$621,640 | |||||
2017-05-12 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale | $88.30 | -1,130 | 14,701 | -7% | -$99,784 | ||||||
| DM | 2017-05-08 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $21.87 | -211,300 | 249,716 | -46% | -$4,622,159 | -2 | ||||
2017-05-08 | INCY | Incyte Corp | Huber Reid M | EVP, Chief Scientific Officer | S - Sale | $119.21 | -8,577 | 36,037 | -19% | -$1,022,464 | -1 | |||||
| D | 2017-05-05 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $121.70 | -3,000 | 10,950 | -22% | -$365,100 | -1 | ||||
| DM | 2017-05-03 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $22.24 | -259,149 | 249,668 | -51% | -$5,762,838 | -1 | 0 | |||
| D | 2017-05-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $23.01 | -89,910 | 184,690 | -33% | -$2,068,519 | -2 | -3 | |||
| D | 2017-05-01 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $124.73 | -5,296 | 12,653 | -30% | -$660,564 | 0 | -5 | |||
| D | 2017-05-01 | INCY | Incyte Corp | Siegel Eric H. | EVP, GC | S - Sale+OE | $124.73 | -1,820 | 16,924 | -10% | -$227,009 | 0 | -5 | |||
| D | 2017-04-28 | INCY | Incyte Corp | Gryska David W | EVP, CFO | S - Sale+OE | $124.26 | -1,389 | 19,015 | -7% | -$172,597 | 0 | -5 | |||
2017-04-28 | INCY | Incyte Corp | Bienaime Jean Jacques | Dir | P - Purchase | $124.26 | +500 | 3,677 | +16% | +$62,130 | 0 | -5 | ||||
| D | 2017-05-01 | INCR | Inc Research Holdings, Inc. | Macdonald Alistair | CEO | S - Sale+OE | $45.00 | -9,467 | 74,468 | -11% | -$426,015 | -6 | -1 | |||
| D | 2017-04-19 | SRNE | Sorrento Therapeutics, Inc. | Abg Management Ltd | 10% | P - Purchase | $2.00 | +550,000 | 8,132,536 | +7% | +$1,100,000 | +6 | +24 | |||
2017-04-19 | SRNE | Sorrento Therapeutics, Inc. | Ji Henry | Pres, CEO | P - Purchase | $2.00 | +100,000 | 2,260,869 | +5% | +$200,000 | +3 | +15 | ||||
| D | 2017-04-17 | PRAH | Pra Health Sciences, Inc. | Baddour Linda | EVP, CFO | S - Sale+OE | $63.59 | -196,393 | 0 | -100% | -$12,488,631 | +1 | +1 | |||
| D | 2017-04-13 | SRNE | Sorrento Therapeutics, Inc. | Abg Management Ltd | 10% | P - Purchase | $2.00 | +2,500,000 | 7,582,536 | +49% | +$5,000,000 | -15 | -4 | |||
2017-04-13 | INCY | Incyte Corp | Bienaime Jean Jacques | Dir | P - Purchase | $139.66 | +1,000 | 3,177 | +46% | +$139,660 | 0 | -2 | ||||
| D | 2017-04-07 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale+OE | $137.88 | -32,000 | 14,648 | -69% | -$4,412,310 | +2 | -7 | -13 | ||
| D | 2017-04-10 | INCY | Incyte Corp | Siegel Eric H. | EVP, GC | S - Sale+OE | $140.18 | -4,043 | 16,785 | -19% | -$566,748 | +2 | -7 | -13 | ||
| D | 2017-04-10 | INCY | Incyte Corp | Gryska David W | EVP, CFO | S - Sale+OE | $138.00 | -41,528 | 19,015 | -69% | -$5,730,864 | +2 | -7 | -13 | ||
2017-04-07 | INCY | Incyte Corp | Bienaime Jean Jacques | Dir | P - Purchase | $139.48 | +1,000 | 2,177 | +85% | +$139,480 | +2 | -7 | -13 | |||
| D | 2017-04-03 | EXEL | Exelixis, Inc. | Marchesi Vincent T | Dir | S - Sale+OE | $21.30 | -10,000 | 120,070 | -8% | -$213,000 | -4 | -5 | +6 | ||
2017-03-31 | CASC | Cascadian Therapeutics, Inc. | Myers Scott Dunseth | Pres, CEO | P - Purchase | $4.11 | +2,000 | 41,416 | +5% | +$8,229 | -3 | +1 | +9 | |||
| D | 2017-04-03 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $23.74 | -1,543 | 57,298 | -3% | -$36,631 | -1 | +1 | +38 | ||
| D | 2017-04-03 | INCR | Inc Research Holdings, Inc. | Gaenzle Christopher L | CAO, GC, Sec | S - Sale+OE | $45.70 | -4,733 | 48,317 | -9% | -$216,298 | -1 | -2 | -8 | ||
| D | 2017-03-31 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale+OE | $21.57 | -5,150 | 72,960 | -7% | -$111,086 | -2 | -6 | +7 | ||
2017-03-28 | CASC | Cascadian Therapeutics, Inc. | Fyfe Gwen A. | Dir | P - Purchase | $4.12 | +1,666 | 3,332 | +100% | +$6,857 | 0 | -9 | +3 | |||
| D | 2017-03-28 | PRAH | Pra Health Sciences, Inc. | Shannon Colin | Pres, CEO | S - Sale+OE | $64.00 | -50,000 | 0 | -100% | -$3,200,000 | 0 | -1 | -2 | ||
| D | 2017-03-27 | PRAH | Pra Health Sciences, Inc. | Dockhorn David W | EVP, CCO | S - Sale+OE | $62.00 | -85,182 | 0 | -100% | -$5,281,284 | 0 | 0 | -2 | ||
2017-03-27 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale | $21.02 | -6,884 | 267,946 | -3% | -$144,702 | -1 | 0 | +3 | |||
2017-03-24 | SNMX | Senomyx Inc | Gray Mary Ann | Dir | P - Purchase | $1.00 | +10,000 | 10,000 | New | +$10,000 | +2 | +2 | -10 | |||
| D | 2017-03-22 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale+OE | $20.54 | -23,787 | 274,830 | -8% | -$488,585 | +2 | +1 | +2 | ||
| M | 2017-03-22 | SNMX | Senomyx Inc | Poyhonen John | Pres, CEO | P - Purchase | $0.98 | +50,000 | 158,293 | +46% | +$49,027 | +1 | +1 | -7 | ||
2017-03-20 | CASC | Cascadian Therapeutics, Inc. | Myers Scott Dunseth | Pres, CEO | P - Purchase | $3.93 | +1,000 | 39,416 | +3% | +$3,927 | +7 | +13 | +8 | |||
| D | 2017-03-20 | EXEL | Exelixis, Inc. | Feldbaum Carl B | Dir | S - Sale+OE | $21.77 | -10,000 | 48,721 | -17% | -$217,700 | 0 | +4 | +3 | ||
| D | 2017-03-20 | EXEL | Exelixis, Inc. | Papadopoulos Stelios | Dir | S - Sale+OE | $21.66 | -10,000 | 1,238,471 | -1% | -$216,600 | 0 | +4 | +3 | ||
| D | 2017-03-17 | INCY | Incyte Corp | Brooke Paul A | Dir | S - Sale+OE | $147.75 | -20,000 | 196,756 | -9% | -$2,955,000 | -5 | -6 | -15 | ||
| DM | 2017-03-16 | INCY | Incyte Corp | Friedman Paul A | Dir | S - Sale+OE | $148.72 | -50,000 | 297,518 | -14% | -$7,436,164 | -5 | -6 | -15 | ||
| D | 2017-03-15 | EXEL | Exelixis, Inc. | Willsey Lance | Dir | S - Sale+OE | $22.86 | -10,000 | 568,273 | -2% | -$228,600 | 0 | -8 | -3 | ||
| D | 2017-03-15 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $22.53 | -50,007 | 172,027 | -23% | -$1,126,658 | 0 | -8 | -3 | ||
2017-03-06 | BHRT | U.S. Stem Cell, Inc. | Murphy William P Jr | Dir | P - Purchase | $0.02 | +1,200,000 | 1,564,039 | +330% | +$24,000 | ||||||
| D | 2017-03-16 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale+OE | $90.00 | -11,717 | 63,566 | -16% | -$1,054,530 | +1 | -2 | -2 | ||
2017-03-13 | EXEL | Exelixis, Inc. | Cohen Charles | Dir | S - Sale | $21.82 | -10,000 | 238,180 | -4% | -$218,200 | +5 | +1 | -4 | |||
2017-03-13 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale | $21.16 | -2,945 | 343,170 | -1% | -$62,316 | 0 | +1 | +9 | |||
2017-03-13 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale | $21.16 | -1,983 | 54,153 | -4% | -$41,960 | 0 | +1 | +9 | |||
2017-03-13 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | S - Sale | $21.16 | -12,059 | 907,418 | -1% | -$255,168 | 0 | +1 | +9 | |||
2017-03-13 | EXAS | Exact Sciences Corp | Arora Maneesh | COO | S - Sale | $21.16 | -5,574 | 634,537 | -1% | -$117,946 | 0 | +1 | +9 | |||
2017-03-10 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale | $89.71 | -3,191 | 69,781 | -4% | -$286,254 | 0 | +1 | -3 | |||
2017-03-10 | CRL | Charles River Laboratories International Inc | Johst David P | Corporate EVP | S - Sale | $89.44 | -7,307 | 181,255 | -4% | -$653,540 | 0 | +1 | -3 | |||
| D | 2017-03-10 | CRL | Charles River Laboratories International Inc | Johst David P | Corporate EVP | S - Sale+OE | $89.06 | -34,593 | 188,562 | -16% | -$3,080,932 | 0 | +1 | -3 | ||
| D | 2017-03-10 | EXEL | Exelixis, Inc. | Marchesi Vincent T | Dir | S - Sale+OE | $21.98 | -40,000 | 120,070 | -25% | -$879,200 | +1 | +1 | -5 | ||
| D | 2017-03-03 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale+OE | $23.04 | -100,000 | 246,617 | -29% | -$2,303,678 | -2 | -2 | -4 | ||
| DM | 2017-03-03 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $22.72 | -200,000 | 249,523 | -44% | -$4,544,000 | -2 | -2 | -4 | ||
2017-03-03 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $23.04 | -2,500 | 140,400 | -2% | -$57,600 | -2 | -2 | -4 | |||
2017-03-06 | CRL | Charles River Laboratories International Inc | Barbo William D | Corporate EVP, CCO | S - Sale | $87.90 | -1,900 | 20,924 | -8% | -$167,014 | +1 | +1 | 0 | |||
| D | 2017-03-06 | CRL | Charles River Laboratories International Inc | Barbo William D | Corporate EVP, CCO | S - Sale+OE | $87.78 | -12,548 | 22,824 | -35% | -$1,101,409 | +1 | +2 | +1 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |